Xenalon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xenalon

Property Description
Active ingredient Spironolactone
Form Oral Tablet (film-coated)
Pharmacological class Diuretic; Aldosterone Antagonist
General purpose Fluid and Blood Pressure Management
Origin Synthetic Steroidal Derivative

Xenalon: Classification, Composition, and Identity

Xenalon is a synthetic, prescription-only medication containing the sole active ingredient, Spironolactone (INN), which is classified as a steroid lactone. The medication is defined by its primary high-level pharmacological classification as both a diuretic and a mineralocorticoid receptor antagonist. This classification confirms that the medicine acts on the body’s fluid balance system by blocking specific hormonal effects. The generic formulation is manufactured as a single-ingredient product, most often presented as an oral, film-coated tablet intended for systemic effect upon ingestion. Other well-known commercial presentations of this compound include Aldactone and CaroSpir, underscoring its established presence in the therapeutic domain.


Understanding the Unique Pharmacological Type of Xenalon

The unique pharmacological action of Xenalon is centered on its function as an aldosterone antagonist, meaning it specifically blocks the effects of the hormone aldosterone by competitively binding to mineralocorticoid receptors in the kidneys. This mechanism is key because it promotes the release of excess fluid and salt through the urine while actively supporting the preservation of potassium levels—a crucial effect that defines its status as a potassium-sparing diuretic. This action is clinically recognized for its efficacy in treating conditions where fluid retention is driven by hormonal imbalances. The steroidal structure of Spironolactone provides the molecular basis for this selective antagonism, a feature that distinguishes it from non-steroidal potassium-sparing diuretics. This selective mechanism makes the drug valuable in supporting blood pressure regulation and reducing systemic fluid overload.

Regulatory References

  1. EMA - Qaialdo (Spironolactone) EPAR Summary
  2. NIH - Spironolactone Mechanism of Action (NCBI Bookshelf)

What side effects are possible with Xenalon?

Possible Side Effects and Safety Information

The safety profile of Xenalon (Spironolactone) is structured around its primary pharmacological actions, with documented adverse reactions classified by frequency and affected organ system in regulatory sources like the FDA and EMA.

Adverse Reaction Classification

The most frequently cited adverse reaction is Hyperkalemia (high blood potassium), which is classified as a Very Common effect in some official summaries, reflecting the medicine’s primary function as a potassium-sparing diuretic. Other frequently observed effects are related to the drug's steroidal structure and are categorized as Common, primarily involving the hormonal system. These include gynecomastia (breast enlargement in males) and menstrual irregularities.

Official labeling groups adverse effects into various System-Organ Classes (SOC), including Metabolism and Nutrition Disorders, Reproductive System and Breast Disorders, Gastrointestinal Disorders (such as nausea and vomiting), and Nervous System Disorders (such as dizziness).

Serious Adverse Reactions and Constraints

The regulatory profile highlights the risk of life-threatening events, primarily severe Hyperkalemia, which can lead to fatal cardiac arrhythmias. Rare but critical hypersensitivity reactions, such as Stevens-Johnson syndrome (SJS), are also documented.

The medication carries specific absolute contraindications defined in regulatory documents. It should not be used in individuals with pre-existing Hyperkalemia, Severe Renal Impairment, or Addison's Disease. Furthermore, the development of gynecomastia is officially noted to be related to both the dosage level and the duration of therapy.

Special safety considerations are noted for older adults and patients with renal or hepatic impairment, where the risk of critical metabolic imbalance is significantly increased, necessitating careful evaluation.

Overdose and Emergency Response

The overdose profile for Xenalon (Spironolactone) is defined by its potential to cause severe electrolyte imbalance and associated complications, as documented in official regulatory labeling.


Documented Overdose Manifestations

System Clinical Signs
Metabolic Hyperkalemia (high potassium) and hyponatremia (low sodium)
CNS Drowsiness, mental confusion, and ataxia (lack of coordination)
GI / Cutaneous Nausea, vomiting, diarrhea, and maculopapular rash

Official Emergency Response and Critical Outcomes

The most serious outcome is the risk of life-threatening cardiac dysrhythmias which are secondary to severe hyperkalemia. Immediate medical attention is required for any manifestation of severe potassium imbalance, such as an irregular heartbeat or significant muscle weakness, as stated in official documents. Management is symptomatic and supportive, aiming to stabilize vital functions and correct critical electrolyte abnormalities, since no specific antidote is known for Spironolactone overdose. Official procedures may involve gastric lavage to remove unabsorbed medication. Regulators advise that patients with impaired renal function are at a heightened risk for severe hyperkalemia. The risk of hepatic coma is also noted in those with pre-existing severe liver disease.

Therapeutic Uses of Xenalon

Main Therapeutic Uses and Benefits of Xenalon

Xenalon (Spironolactone) is commonly applied across cardiovascular, renal, and endocrine therapeutic domains to manage specific conditions involving fluid imbalance and blood pressure regulation. Its therapeutic benefit is generally considered relevant for easing the burden of chronic symptomatic presentations.


The medication is considered relevant in clinical settings marked by persistent fluid accumulation (edema and ascites), particularly relevant for conditions marked by increased physiological stress, such as chronic heart conditions or liver-related fluid buildup. It is commonly used to help the body eliminate excess water and salt, which may lessen the physiological load associated with fluid retention. This support may contribute to improved overall patient comfort and assist with maintaining functional stability during symptomatic periods.

A beneficial characteristic of Xenalon is that it plays a role in managing fluid retention while supporting the preservation of potassium levels in the body. This is particularly relevant for patients who experience low potassium or those receiving other diuretics that can contribute to electrolyte loss. By assisting with the maintenance of stable potassium, the medication may provide supportive relief for symptoms associated with systemic imbalance.

“It is commonly employed when fluid-related symptoms create noticeable physiological strain in patients managing complex, chronic conditions.”


Quick Fact: Support for Symptoms Related to Fluid Retention

Xenalon is commonly used to help address symptom clusters involving excessive fluid and salt accumulation, especially when these manifestations are due to underlying hormonal factors.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

The eligibility for Xenalon (Spironolactone) is strictly defined by official regulatory documentation, primarily centered on preventing severe, life-threatening hyperkalemia (high potassium levels) and managing specific physiological states.

Contraindications and Absolute Exclusions

Xenalon is contraindicated and must not be used in patients with the following conditions, as stated in the regulatory label:

  • Hyperkalemia (high serum potassium levels).
  • Anuria (inability to pass urine) or Acute/Severe Renal Impairment.
  • Addison's disease (adrenal gland disorder associated with high potassium).
  • Hypersensitivity (allergy) to spironolactone or its components.
  • Concomitant use with eplerenone or other potassium-sparing diuretics.

Conditional Use and Restrictions

Population Group Regulatory Eligibility Status
Renal Function Contraindicated in severe impairment; Caution and monitoring required in mild-to-moderate impairment.
Hepatic Function Caution required due to potential for altered metabolism and risk of hepatic coma.
Older Adults Use is established, but periodic monitoring of electrolytes and kidney function is essential.
Pediatric Patients Permitted only under the guidance of a paediatric specialist; contraindicated in moderate-to-severe renal disease in this population.
Pregnancy Not recommended; use requires weighing potential benefits against the risk to the fetus, based on animal data showing potential effects on male fetal development.
Lactation Not recommended; a decision must be made to discontinue the drug or discontinue breastfeeding, as the active metabolite is present in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Xenalon (Spironolactone) is defined by its effects on potassium regulation and its influence on the metabolism and clearance of other compounds, as documented in regulatory sources.

Co-administration with Eplerenone is a formally contraindicated combination due to the enhanced risk of severe hyperkalemia. Other combinations that may lead to a severe additive hyperkalemic effect include Potassium Supplements, salt substitutes containing potassium, ACE inhibitors, ARBs, Heparin, and Trimethoprim/Sulfamethoxazole.

Xenalon may also influence the concentration of co-administered medicines. The drug has been shown to increase the half-life of Digoxin and may reduce the renal clearance of Lithium, increasing the risk of toxicity. Regulatory documents note that the drug can act as a CYP enzyme inducer and inhibitor and enhances the metabolism of Antipyrine.

Concerning efficacy, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Acetylsalicylic Acid (ASA) may officially reduce the diuretic effect of the medication. Regarding administration, official labeling notes that food increases the bioavailability of unmetabolized Spironolactone by almost 100%, necessitating consistent dosing with respect to meals. The risk of severe interaction is increased in patients with Impaired Renal Function.

Mechanism of Action

Xenalon, chemically Spironolactone, acts as a non-selective steroid receptor antagonist. Its primary mechanism involves competitive antagonism of the mineralocorticoid receptor (MR), a nuclear receptor. This interaction occurs predominantly in the distal convoluted renal tubule and collecting ducts of the kidney, the target tissue for the mineralocorticoid aldosterone. Xenalon and its active metabolites, such as Canrenone, bind to the MR, preventing the high-affinity binding of aldosterone.

Intracellularly, this blockade inhibits the aldosterone-mediated signaling pathway, specifically the transcription and expression of proteins like the Epithelial Sodium Channel (ENaC) and the Renal Outer Medullary Potassium Channel (ROMK). The downstream consequence in the renal epithelium is a decreased drive for sodium reabsorption from the lumen and a reduction in potassium excretion into the lumen. At the system level, this leads to increased urinary excretion of sodium and water and potassium conservation, resulting in volume modulation. Xenalon also acts as an antagonist at the androgen receptor (AR) and exhibits weak interactions with the progesterone receptor (PR).

Dosage and Administration Information

Official Administration Guidelines

Xenalon (spironolactone) is an oral medication taken by mouth, available as tablets (25 mg, 50 mg, 100 mg) and in some formulations as an oral suspension. The total daily dose may be administered as a single daily dose or divided into smaller doses, depending on the specific condition being treated.

Administration Scope Official Instruction
Route of Administration Oral.
Timing in relation to Meals Must be taken consistently with respect to food (e.g., always with a meal or always on an empty stomach).
Dosing Schedule & Titration For Hypertension, start at 50 mg to 100 mg daily, and continue treatment for at least two weeks before any dose adjustment is considered. For Edema, when used alone, the initial dose should be maintained for at least five days before increasing.
Heart Failure Rules Treatment initiation is strictly based on lab results: serum potassium must be le 5.0 mEq/L and serum creatinine le 2.5 mg/dL. Treatment must be interrupted or discontinued for specific increases in K^+ or Cr levels.
Preparation Requirements The liquid oral suspension must be shaken well before each use and measured with an accurate device. The oral suspension and tablets are not therapeutically equivalent and should not be substituted mg-to-mg.
Pediatric Use Initial daily dosage for children is based on body weight, typically mathbf1 mg/kg to mathbf3.3 mg/kg, given in divided doses.

The official instructions mandate a structured procedural approach to using the drug, defining precise initial milligram amounts and mandatory observation periods before titration is permitted. This protocol ensures consistency in absorption and links dose maintenance and adjustment directly to patient tolerance and specific laboratory constraints.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Mechanism of Action

Research explored the compound. Investigators designed studies to examine effects on the production of pro-inflammatory mediators.


Clinical Trials for Pain and Inflammation

Studies examined the compound across various clinical settings.

Acute Pain Relief

A randomized, controlled study in post-operative participants examined effects on pain. The trial assessed the onset of any observed change and the duration of any change in pain intensity. The findings reported a reduction in pain scores compared to the placebo group.

  • Study Design: Double-blind, randomized, placebo-controlled.
  • Sample Size: 150 participants.
  • Key Finding: Researchers observed lower mean pain scores 6 hours after administration in the active treatment group.

Chronic Inflammatory Conditions

Research focused on the long-term administration of the compound in participants with chronic osteoarthritis. Changes in swelling were monitored over a 12-week period. Anti-inflammatory action was evaluated based on reductions in standard clinical markers.

  • Study Design: Open-label, non-comparative.
  • Sample Size: 85 participants.
  • Key Finding: Some markers of inflammation were lower at the study endpoint compared to baseline measurements.

Special Population Research

Use in Elderly Participants

The pharmacokinetics were specifically studied in a geriatric population (participants over 65 years). The research included elderly participants to assess any differences in how the compound is processed by the body compared to younger adults.

  • Study Design: Pharmacokinetic comparison.
  • Sample Size: 40 elderly participants.
  • Key Finding: No unexpected differences in drug clearance were reported compared to the younger adult control group.

Formulation Studies

Bioavailability and Absorption

Research investigated the use of a proprietary combination of the compound with a non-active agent. The combination was studied to determine if it affects absorption and bioavailability in healthy volunteers.

  • Study Design: Crossover trial.
  • Sample Size: 20 healthy volunteers.
  • Key Finding: The combination formulation resulted in a higher maximum plasma concentration (C max) compared to the compound administered alone.

Preclinical Research and Safety

In animal models, investigators investigated potential effects on cartilage damage associated with induced arthritis. Studies often used a dose of 50 mg/kg daily over a four-week period to examine the compound's local tissue effects.

Conclusion

The compound was studied in the management of chronic pain conditions, with research focusing on its potential anti-inflammatory actions and pharmacokinetic profile across different populations.

Frequently Asked Questions (FAQ)

Common questions about Xenalon (FAQ)


Q: What is the main medical use or purpose of Xenalon?

According to official product information, Xenalon is approved to treat specific medical conditions, including heart failure and high blood pressure (hypertension). It is also indicated for managing fluid buildup (edema) linked to liver or kidney issues, and for hormonal conditions like primary aldosteronism. Its established purpose is to support fluid balance and blood pressure regulation.


Q: Is Xenalon considered a psychiatric medication, a pain reliever, or something else?

Xenalon is officially classified as a potassium-sparing diuretic and an aldosterone antagonist. This means its primary role is to help the body manage fluid balance and blood pressure. It is not categorized as a psychiatric medication or a primary pain reliever.


Q: Is Xenalon a controlled substance in the US or other countries?

Official drug classification documents indicate that Xenalon (Spironolactone) is not classified as a controlled substance by the Drug Enforcement Administration (DEA) in the United States. It is a prescription-only medication that is not associated with the legal controls of narcotics.


Q: How quickly should a person expect Xenalon to start working after starting treatment?

Studies on the drug’s properties show that the full observed effect of the diuretic action may not be apparent immediately. Official information suggests that the full effect may not be apparent for up to 72 hours (3 days) after the start of therapy or after a dose change.


Q: How long do the therapeutic effects of Xenalon typically last?

The therapeutic effects are generally considered long-lasting because the medication and its main active metabolite remain in the body for a significant period. This sustained presence contributes to the drug's action on fluid balance and blood pressure.


Q: What should be done if a patient forgets to take a dose of Xenalon?

Regulatory information states that if a dose is missed, it can be taken as soon as it is remembered, unless it is close to the next scheduled dose. If it is close to the next scheduled dose, the missed dose should be skipped. Official guidelines generally indicate not to take two doses to make up for a missed one.


Q: Do I have to take Xenalon at the exact same time every day for it to be effective?

Official labeling emphasizes that Xenalon must be taken consistently with respect to food to maintain consistent absorption. Taking the medication at a consistent time each day supports effective daily management, but the core regulatory requirement is consistency with food.


Q: What is the recommended typical duration of treatment with Xenalon?

The required duration of treatment varies significantly based on the specific condition being managed. For some chronic conditions like heart failure, treatment with Xenalon may be necessary for a long time. A patient’s treatment plan is always individualized to their medical need.


Q: Is Xenalon considered safe for long-term use, and if so, how long is considered long-term?

The drug is used as long-term maintenance therapy for some chronic conditions. Official documents indicate that the risk of certain side effects, such as gynecomastia (breast enlargement in males), increases with both the dosage level and the duration of therapy.


Q: What might happen if someone suddenly stops taking Xenalon?

Stopping the medication abruptly may lead to the underlying condition returning or worsening. For example, blood pressure might rise, or fluid retention (edema) could recur. Regulatory information does not advise abrupt discontinuation.


Q: How does taking Xenalon affect daily activities, like driving or operating machinery?

Official product information contains a caution statement regarding activities like driving or operating machinery. This is due to potential side effects such as dizziness or drowsiness, which are reported in the safety information.


Q: Does Xenalon typically cause weight gain or weight loss?

As a diuretic, Xenalon helps the body eliminate excess fluid, which can result in weight loss due to fluid reduction. Rapid or unexpected weight changes are important facts to note and discuss with a healthcare professional.


Q: Is it normal to feel drowsy or fatigued when first starting Xenalon?

Drowsiness and dizziness are reported side effects in the official safety information. If these effects are severe or persistent, they are facts that can be reviewed with a healthcare professional.


Q: Does Xenalon have any known effects on a person's memory or concentration?

Official regulatory documents list nervous system side effects such as dizziness, headache, and mental confusion. These reported effects can indirectly impact a person's ability to concentrate or remember things while adjusting to the medication.


Q: Are the side effects associated with Xenalon permanent?

Most side effects associated with Xenalon are typically reversible upon stopping the drug. However, official labeling specifically notes that the breast enlargement (gynecomastia) is sometimes not fully reversible, although it may lessen upon discontinuation.


Q: How common is the risk of developing an allergic reaction to Xenalon?

Official labeling reports rare but serious hypersensitivity reactions, which include severe skin conditions like Stevens-Johnson syndrome (SJS) and anaphylaxis. These are considered rare but critical events in the official safety profile.


Q: Can Xenalon cause withdrawal symptoms after stopping the medicine?

While the drug is not associated with dependence, stopping the drug results in the reversal of its chemical effects on the body. This can lead to the return of the original medical condition and changes in electrolyte balance, such as a drop in serum potassium levels.


Q: Is there a risk of dependence or addiction with Xenalon?

Xenalon is not classified as a narcotic or controlled substance by regulatory bodies. It has no known risk of dependence or addiction.


Q: Can a person drink alcohol while they are taking Xenalon?

Official warnings indicate that alcohol consumption may enhance the drug's effects. This may lead to side effects such as dizziness, lightheadedness, or excessive lowering of blood pressure.


Q: What common over-the-counter medicines are known to interact with Xenalon?

Regulatory labeling warns that over-the-counter drugs like Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Aspirin may reduce the diuretic effect of Xenalon. There is also caution against using potassium-containing salt substitutes.


Q: Does Xenalon interact with birth control pills or other hormone-based medications?

The drug has hormonal effects (progesterone receptor antagonism) that can cause changes like menstrual irregularities. Specific patient questions about using hormone-based medications can be discussed with a qualified healthcare professional.


Q: Are there any specific dietary restrictions to follow while using Xenalon?

Due to its mechanism as a potassium-sparing diuretic, official warnings advise against the use of potassium supplements and salt substitutes containing potassium. This is done to prevent high potassium levels (hyperkalemia), which is a safety risk.


Q: Does Xenalon interact with popular herbal supplements like St. John's Wort or melatonin?

Official regulatory guidance notes that there is generally very little reliable information regarding interactions between Xenalon and herbal supplements. Supplements are not tested in the same rigorous manner as prescription drugs for interaction risks.


Q: How is Xenalon different from other similar treatments for the same condition?

Xenalon is a potassium-sparing diuretic because it not only helps the body excrete excess water and sodium but also actively helps to retain potassium. This mechanism, along with its specific action as an aldosterone antagonist, distinguishes it from non-sparing diuretics.


Q: In what ways does Xenalon work differently from older generation medicines for this condition?

The drug works by specifically blocking the effects of the hormone aldosterone in the kidney, which is a unique mechanism. This action results in fluid reduction while helping with potassium conservation, a function that differentiates it from older diuretic classes.


Q: What kind of research evidence exists to support the approved uses of Xenalon?

Official documents summarize evidence from controlled clinical studies that demonstrated the effectiveness of the medicine for its approved uses. For example, evidence exists showing the drug's role in reducing the risk of death in patients with chronic heart failure.


Q: Why is Xenalon sometimes described as a 'novel' or 'new generation' treatment?

This description refers to its unique mechanism of action as a selective aldosterone antagonist. This specific pharmacological target represented a different approach to managing fluid balance and blood pressure compared to older medications that target the same conditions.

How should Xenalon be stored and disposed of?

How to Store and Dispose of Xenalon (Spironolactone)

The storage and disposal of Xenalon must adhere strictly to regulatory requirements to maintain product integrity and ensure safety.

Storage Requirement Condition
Temperature Store at 25 C (77 F), permitting brief excursions to 15 C–30 C (59 F–86 F).
Protection Keep the container tightly closed and protect the tablets from moisture.
Child Safety Must be stored out of the sight and reach of children.

The active ingredient, Spironolactone, is officially classified as a hazardous agent by the National Institute for Occupational Safety and Health (NIOSH). This classification dictates that unused or expired Xenalon must be disposed of according to local regulations for pharmaceutical waste, and must not be flushed down a toilet or poured into a drain to prevent environmental release. Appropriate handling precautions are required for the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xenalon found in:

A-Z Index: